← Back to headlines
Revolution Medicines Stock Surges Following Positive Pancreatic Cancer Drug Trial Data
Revolution Medicines announced that its highly anticipated drug for pancreatic cancer, daraxonrasib, has succeeded in a Phase 3 clinical trial, leading to a surge in the company's stock. This represents a potential breakthrough in treating the aggressive disease.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Oldest Known Plague Outbreak Discovered in Siberia Dating Back 5,500 Years
just now
Extreme Training: What Heat Training Does to the Body
just now
President Tinubu Applauded for New Federal Medical Centre in Delta State
16m ago
Parliaments must prioritise gender-responsive budgets to fight violence against women and girls – Kenyan advocate
1h ago